The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

    3 Oct, 2022

    In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment.

    Read our media release here.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...